REDWOOD CITY, Calif., Jan. 25, 2018 /PRNewswire/ — ARMO BioSciences, Inc. (“ARMO”), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross…
